drugset / Trial / NCT02855411
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine whether PF-04958242 is safe and effective in the treatment of cognitive dysfunction in schizophrenia subjects
Timeline
- Start
- 2016-08-29
- Primary completion
- 2016-09-26
- Completion
- 2016-09-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PESAMPATOR | Small molecule | 0.15 mg | Oral |
| Subject | PESAMPATOR | Small molecule | 0.5 mg | Oral |